How we work

We break down the traditional silos across the life-science industry and share information to increase accountability and facilitate progress.

IFPMA serves as the secretariat of the AMR Industry Alliance with the responsibility of implementing the activities endorsed by the Board. The Board is the governing body of the AMR Industry Alliance. It is responsible for the planning and oversight of AMR Industry Alliance’s activities.

Deborah O’Neil

BioIndustry Association

A biotechnology entrepreneur and immunologist by training, Deborah has over two decades of experience in anti-infective drug discovery research and development. Deborah studied at University College London and then worked in postdoctoral positions in internationally acclaimed laboratories in San Diego and Ghent before moving to Aberdeen (to the Rowett Research Institute, now part of the University of Aberdeen) where she founded NovaBiotics in 2004. The business has since become a leading global biotechnology business, developing a portfolio of first-in-class anti-infective therapies addressing the urgent, unmet need for safe and effective antimicrobials including Nylexa for COVID-19. NovaBiotics is on the front line of the fight against antimicrobial resistance (AMR).

Deborah is a Board member of the UK’s BioIndustry Association, a Director and founding member of the BEAM Alliance (Biotechs of Europe innovating in Anti-Microbial Resistance), was a member of the Scottish Life Sciences Industry Leadership Group and sit on the Boards of the Scottish Life Sciences Association and Opportunity North East Life Science/BioAberdeen. Deborah serves as Chairperson of the UK’s Medicines Discovery Catapult-Cystic fibrosis (CF) Trust’s working group on antimicrobials in CF and sits on the UK BioIndustry Association’s working group on AMR. Elected as a Fellow of the Royal Society of Edinburgh in 2018 and a Fellow of the Royal Society of Medicine. Named as one of the 20 women leaders in European biotech in 2019, one of the 30 top female leaders in UK Healthcare in 2018 and one of the 15 leading women European biotech in 2017. In 2020, Deborah was made OBE in the Queen’s Birthday Honours list, for services to biotechnology, industry and charity.

Industry associations representatives

Eric Bacqué

Evotec

Eric is a chemist by training. He is currently heading the Medicinal Chemistry Group of Evotec ID Lyon while being the Evotec Innovate AMR portfolio leader. He worked for Sanofi and its predecessor companies (Rhône-Poulenc and Aventis) for almost 30 years before joining Evotec mid-2018. Eric has been working in the field of infectious diseases (antibacterial, anti-mycobacterials, anti-virals and anti-fungals) for more than 20 years. In the field of antibacterials, he has conducted or contributed to multiple research and preclinical development projects across numerous antibacterial targets and chemical series. This work led for instance  to the clinical antibacterial candidates NXL-101 and NXL-103. Eric is particularly committed to the fight against AMR and, along these lines, he has contributed in recent years, as  EFPIA co-coordinator of the IMI ENABLE consortium and as Project Lead for the GNA NOW consortium, to various European initiatives aiming at developing new classes of antibacterials active on the key drug-resistant Gram-negative pathogens.

Research-based pharmaceutical companies representatives

Fred Tenover

Cepheid

Dr. Tenover is Vice President for Scientific Affairs at Cepheid, where he has worked since 2008.  He also serves as Consulting Professor of Pathology at Stanford University School of Medicine, Adjunct Professor of Epidemiology in the Rollins School of Public Health at Emory University, and Consulting Professor of Biology at the University of Dayton. Prior to joining Cepheid, he served for 18 years at the Centers for Disease Control and Prevention (CDC) in Atlanta as Associate Director for Laboratory Science in the Division of Healthcare Quality Promotion, where he directed the antimicrobial susceptibility testing laboratories, and the staphylococcal, anaerobe, and nosocomial gram-negative organism identification laboratories. His research team discovered the KPC carbapenem resistance gene and several other key resistance determinants. He then became the Director of the Office of Antimicrobial Resistance for CDC. Dr Tenover was a member of the CLSI Antimicrobial Susceptibility Testing Subcommittee for 17 years, developing novel test methods for resistance detection and interpretive criteria for new antimicrobial agents. At Cepheid, in addition to working on strategies for new product development and innovation, his research team focuses on rapid detection of healthcare-associated infections and mechanisms of carbapenem resistance. He is a Diplomate of the American Board of Medical Microbiology and a Fellow of both the American Academy of Microbiology and the Infectious Disease Society of America. He has authored over 330 peer-reviewed journal articles and has written or edited 11 books on microbiology and molecular diagnostics.

Diagnostics companies representatives

Joe Larsen

Venatorx Pharmaceuticals

Dr. Larsen is a globally recognized leader in the area of public health preparedness with more than 20 years’ experience. As Vice President, Strategic Portfolio Development at Venatorx Pharmaceuticals, Dr. Larsen is responsible for identifying new growth opportunities and translating the company’s rich internal programs toward strategic public and private partnerships.

Previously, Dr. Larsen served as Director of the Division of CBRN Medical Countermeasures within the Biomedical Advanced Research Development Authority (BARDA). In that role, he oversaw a $2.8B fund for the late-stage development and procurement of medical products for use during public health emergencies and a $530M annual advanced research and development fund. Additionally, Dr. Larsen supported the development and regulatory approval for a novel smallpox antiviral drug, two novel antibiotics, and a cytokine therapy to treat the hematopoietic effects of acute radiation exposure. He also led the establishment of Project Bioshield programs to develop vaccine and therapeutics to safe guard the American public from future Ebola virus outbreaks. Dr. Larsen was the lead for BARDA’s work on combating antibiotic resistant bacteria and was an executive member and founder of CARB-X, a novel $450M public private partnership focused on promoting innovation in antibacterial drug development.  Dr. Larsen has also been involved in discussing potential reforms to the economic incentive structures for antibacterial drug development.

Previously, Dr. Larsen served as Chief of the Broad Spectrum Antimicrobials program at BARDA. In that role, Dr. Larsen oversaw a portfolio of approximately $1.2B in programs that supported the development of novel antibacterial and antiviral drugs. Dr. Larsen also served as the BARDA representative on the U.S. Transatlantic Task Force on Antimicrobial Resistance, and as a Senior Science and Technology Manager at the Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBDP) within the Defense Threat Reduction Agency (DTRA).

Dr. Larsen was an American Association for the Advancement of Science (AAAS) fellow at the Department of Homeland Security. Additionally, he was a 2005 National Academy of Science Christine Mirzayan fellow with the Board of Life Sciences. Dr. Larsen received his Ph.D. in Microbiology from the Uniformed Services University of the Health Sciences and his B.A. with honors from the University of Kansas.

Biotechnology companies/SMEs representatives

John Billington

GlaxoSmithKline

Head of Health Security and Infectious Disease Policy and Advocacy

John Billington is Head of Health Security and Infectious Disease Policy and Advocacy in the global corporate government affairs department of GSK. In this role, he is responsible for the company’s policy and advocacy strategy for infectious diseases at the enterprise level, with a focus on pandemic preparedness and antimicrobial resistance (AMR).  Prior to this role, John was director of science policy for the global vaccines business and director for U.S. vaccines policy before that. Before joining GSK, John was director of health policy at the Infectious Diseases Society of America (IDSA). At IDSA, John served as lead subject matter expert on vaccines, antibiotics, and medical countermeasures policy. He also launched and coordinated the U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR), a national stakeholder partnership to advance U.S. and global policies and practices in response to AMR.  Earlier in his career, John was a manager in the health reform practice at Avalere Health, a health policy advisory firm. He was also a legislative fellow for health policy in the office of U.S. Senator Sherrod Brown of Ohio.  John received his Juris Doctor and Masters of Public Health from the Ohio State University in Columbus, Ohio. He received his undergraduate degree from Colgate University in Hamilton, New York.

Research-based pharmaceutical companies representatives

Kirsten Nyland

Fresenius-Kabi

Kirsten Nyland has more than 30 years of experience within the pharmaceutical industry in various managerial positions in sales and marketing, strategic planning, research and development, governmental affairs, sustainability and CSR on national, regional and global level.
Today Kirsten is Vice President at Fresenius Kabi leading Environmental & Occupational Management throughout the global organization. In this position, she focuses on enhancing Environment, Sustainability, Health and Safety as well as Occupational Health and Safety to continuously fulfill increasing expectations from internal and external stakeholders.

Generics companies representatives

Kristine Peers

European Federation of Pharmaceutical Industries and Associations

Kristine Peers is General Counsel at the European Federation of Pharmaceutical Industries and Associations (EFPIA) since September 2017.  Her role includes responsibility for EFPIA’s policy solutions to address antimicrobial resistance (AMR).

Through its direct membership of 36 national associations, 39 leading pharmaceutical companies, and a growing number of small and medium-sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients.

Kristine builds on a career combining legal expertise with public policy and government relations. She has worked in various legal and corporate affairs functions at Belgian, European and global level with GlaxoSmithKline and Pfizer. Prior to joining the pharmaceutical industry, Kristine practiced at

the Belgian Bar. She graduated in law from Leuven University, Belgium, and obtained a postgraduate qualification in European Law at the European University Centre in Nancy, France, where she was also visiting lecturer teaching European regulations of medicinal products to health professionals. Throughout her career she had several legal, business and leadership training including at INSEAD and NYU Stern. She is co-founder of the Brussels Pharma Law Group.

Industry associations representatives

Marc Gitzinger

BioVersys

Marc Gitzinger is Chief Executive Officer and co-founder of BioVersys. He has over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset early clinical stage company. Some of these assets will address significant unmet medical needs in infectious conditions such as tuberculosis and hospital acquired Acinetobacter infections. He has raised over $30 mio in equity financing and secured over $20 mio in non-dilutive funding. He has also established several important partnerships with a Big Pharma and other development organizations. Dr. Gitzinger is a multi-award-winning Biotech CEO, having received amongst others the Swiss Technology Award 2011, Venture Kick 2009 and Venture Leaders 2008 and 2017 awards for his work in founding and advancing BioVersys. He is also vice-president of the board of the BEAM Alliance, a European association representing over 60 European and international SMEs active in antimicrobial research and development. Dr. Gitzinger is a young thought leader in the field of antimicrobial research and development. He is passionate about next generation antimicrobial therapies and leads a highly motivated team striving to bring life-saving antimicrobial therapies to patients in need. He is also co-author on several high ranked scientific publications and patents in the field.

Biotechnology companies/SMEs representatives

Masoud Dara, M.D., Ph.D.

Otsuka

Dr Masoud Dara is a physician and public health professional from Belgium with more than 25 years of experience in designing, implementing and evaluating health programs with a focus on infectious diseases in about forty countries across four continents.

Since November 2021, he functions as the Director of Global Health and Alliances at Otsuka Novel Products Group GmbH.

From October 2020 to October 2021, Dr Dara served as the Special Representative of the WHO Regional Director to Belarus, providing strategic guidance and policy dialogue and leading the WHO Country Office activities in the country. From October 2016 to October 2020, he coordinated the WHO Regional Office for Europe’s Communicable Diseases Department and led the WHO/Europe’s Joint Tuberculosis, HIV and viral hepatitis program. Before that, Dr Dara functioned as the WHO Senior Advisor to the European Union for two consecutive years. He led the WHO/Europe’s TB and MDR-TB program between 2010 and 2014. From 2001 to 2010, he served as a Senior Consultant of the Royal Netherlands Tuberculosis Association (KNCV) and functioned as a WHO Medical Officer in Moscow. In the beginning of his international career, Dr Dara worked as a medical doctor and Project Coordinator of Médecins Sans Frontières in Central Asia and as the Head of Belgian Red Cross in Kosovo between 1998 and 2001.

Dr Dara has authored more than 60 publications in peer-reviewed journals and several WHO guidelines. He has been a chair and member of various scientific working groups such as TB Control in Prisons of the International Union Against Tuberculosis and Lung Diseases. Furthermore, in various periods, he served an Associate Editor of International Journal of Tuberculosis and Lung Diseases, a member of the Editorial Board of Eurosurveillance and a member of the Editorial Board of International Journal of Environmental Research and Public Health.

He is fluent in Persian, English, French, Dutch and Russian.

Research-based pharmaceutical companies representatives

Sarah McGill

F. Hoffmann-La Roche AG

Sarah McGill is Senior Director and Head Global Access Product Strategy for Roche.  Sarah joined Roche in 2006 and has held a variety of marketing and market access leadership positions across the pharmaceutical division.  She is responsible for global access strategies across the Roche portfolio including support for lifecycle decisions, regulatory and HTA approvals, pricing, and reimbursement.  Sarah’s team leads Roche’s policy engagement on AMR via IFPMA and EFPIA.  Roche’s commitment to combat AMR and achieve a new Platinum Age for antibiotics R&D is underpinned by substantial investment in the discovery and development of novel antibiotics and the development of diagnostic assays to rapidly identify the type of drug-resistance bacteria responsible for infection.  Roche is proud to join together with industry partners to support AMR Action Fund – a collective venture organized by IFPMA that will contribute more than $1 billion towards novel antibiotic development and support advocacy for a robust and sustainable pipeline of new antibiotics to fight drug-resistant infections.

Research-based pharmaceutical companies representatives

Susan Van Meter

AdvaMedDx

Susan Van Meter is Executive Director of AdvaMedDx. AdvaMedDx represents over 70 manufacturers of innovative in vitro diagnostics (IVD) tests, point-of-care (POC) and laboratory instruments and other technologies, seeking to advance policy to promote innovation and expand access to quality testing.  Based in Washington, D.C., AdvaMedDx is the only advocacy organization exclusively addressing policy issues facing diagnostics manufacturers in the U.S. and around the world.

AdvaMedDx operates as a division of AdvaMed, the Advanced Medical Technology Association. AdvaMed is the world’s largest medical technology association with over 400 member companies that develop medical devices, diagnostic tools, and health information systems.

Given the critical role quality diagnostic tests serve in the fight against drug-resistant infection, AdvaMedDx has led the development of Diagnostic Stewardship recommendations. These recommendations provide practical policy guidance to clinicians on leveraging diagnostic tests to improve informed prescribing of antibiotics as part of any meaningful effort against Antimicrobial Resistance (AMR).

Prior to joining AdvaMedDx in 2018, Ms. Van Meter served as senior vice president at the Healthcare Association of New York State (HANYS) and focused on hospital and health system policy, payment, quality, and health information technology priorities.  She also previously served in the U.S. Department of Health and Human Services, Centers for Medicare and Medicare Services, Office of Legislation.  Ms. Van Meter has an undergraduate and a graduate degree from Villanova University and Boston University, respectively.

Industry associations representatives

Tanya Gottlieb

MeMed

Dr. Tanya Gottlieb serves as Vice President of Scientific Affairs at MeMed, a company pioneering host response technologies. She joined in 2014 and leads MeMed’s international collaborations and non-dilutive funding projects, focused on improving patient management and antibiotic stewardship via tools that support decision making on appropriate use. Before joining MeMed, Dr. Gottlieb was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative start-up developing a universal flu vaccine, where she established relationships with the National Institute of Health (US) and European Commission. Dr. Gottlieb conducted her postdoctoral research at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. She holds a BA in Natural Sciences and a PhD from Cambridge University in the UK and an MBA from the Technion in Israel.

Diagnostics companies representatives

Thomas Cueni

IFPMA

Thomas B. Cueni is Director General of IFPMA, the global association of pharmaceutical research companies, based in Geneva. Thomas Cueni represents the innovative biopharmaceutical industry on the ACT Accelerator, the Access to COVID-19 Tools (ACT) Accelerator, a unique global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines. He is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. Thomas Cueni has been instrumental in creating the AMR Action Fund and he is Chair of the Board of the cross-sectoral AMR Industry Alliance. Prior to joining IFPMA he was Secretary General of Interpharma (Switzerland) and was a member of the Board and Chair of the European Federation of Pharmaceutical Industries and Associations. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”. He served as a Swiss diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basel, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).

Chair

Koen Laenen

Medicines for Europe

Koen Laenen joined Medicines for Europe in November 2018 as Regulatory Affairs and Quality Senior Manager. At Medicines for Europe Koen is responsible for all regulatory, quality and EHS projects concerning the generic pharmaceutical industry in Europe. Prior to Medicines for Europe, Koen was Business Unit Director at Ardena NV leading a team of CMC writers and Regulatory Affairs Officers from 2015 till 2018. Prior to that Koen was working for +10 years for Jubilant Pharmaceuticals NV as Head of Operations. In this function he was overlooking the performance and deliveries of the R&D projects, Site Transfers and Bio-Equivalence Studies to ensure that the planned deliverables were executed on time. And to manage the Regulatory Affairs and Quality Assurance departments in Europe, to timely obtain and maintain all market. Koen has a university degree in biotechnology and prior to starting in the pharmaceutical business he worked for several years as researcher in molecular neurobiology at university of Ghent.

Industry associations representatives

Gareth Morgan

Shionogi

Gareth Morgan is Senior Vice President and Head of Global Portfolio Management for Shionogi. In addition to leading the Portfolio Management team, Gareth is responsible for providing strategic and policy direction related to anti-infective agents, and frequently represents Shionogi on anti-infective related government affairs and policy assignments, particularly those associated with the growing threat of antimicrobial resistance. Gareth has more than 25 years of experience with pharmaceutical and biotech companies, including BMS, Bayer, Genentech (now Roche) and Hoechst-Roussel (now Sanofi). He has led or provided functional and strategic oversight to development programs across multiple geographies and therapeutic areas.

Research-based pharmaceutical companies representatives

Bruce Altevogt

Pfizer

Bruce Altevogt is a Vice President and Head External Medical Engagement within Pfizer Inc.’s Hospital Business Unit, which includes managing the industry leading AMR surveillance program, Atlas. Prior to this role he was a Senior Director of Science Policy and Science Advocacy within Global Policy and International Public Affairs. In this role Dr. Altevogt was responsible for managing policy issues in support of Pfizer’s research & development enterprise, vaccines and was lead for anti-microbial resistance policy. Prior to joining Pfizer Inc. Dr. Altevogt served as a senior program officer on the Board on Health Sciences Policy at the Institute of Medicine, where he led policy initiatives related to basic and translational research, drug discovery and development, and preparedness for catastrophic events. Dr. Altevogt received a doctorate from Harvard University’s Program in Neuroscience and a B.A. from the University of Virginia, where he majored in Biology and minored in South Asian Studies. He is a published author of multiple scientific articles.

Research-based pharmaceutical companies representatives

Paul Schaper

MSD

Paul Schaper, Executive Director, Global Public Policy, leads global policy efforts at MSD in Global Pharmaceuticals, which includes a broad range of therapeutic areas from diabetes to cardiovascular disease, neuroscience, reproductive health, and infectious disease, including hepatitis, HIV, and antibiotics/antifungals. From 2013 – 2017, he served as the Board Member for the Private Sector Constituency on board of the Global Fund for HIV, TB, and Malaria. He currently serves as the Private Sector Alternate Board Member. He earned his B.A. and master’s degrees in public health policy and business administration from Emory University and a master’s degree in clinical psychology from Georgia State University.

Research-based pharmaceutical companies representatives

Adrian Thomas

Johnson & Johnson

Adrian Thomas, M.D., is the Vice President, Global Programs Strategy & Evaluation with the Johnson & Johnson Global Public Health organization. Adrian has a special interest in the fields of public health, commercial and market access strategy, and pharmaceutical policy. He also held numerous roles in market access including Global Head Health Economics & Market Access Medical Devices. He was Global Head of Market Access for Janssen, the pharmaceutical companies of Johnson & Johnson, as well as roles in risk management and drug safety, including Global Head of Benefit Risk Manager and Chief Safety Office for Janssen. Prior to joining J&J, Adrian held roles in regional medical affairs, drug development and product management for Schering-Plough and Eli Lilly. He is a clinical pharmacologist and vascular physician with experience in clinical trials design and methodology. Adrian is a Fellow of the Royal Australasian College of Physicians and the College of Medical Administrator’s. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Melbourne in Australia. He is based in New Hope, Pennsylvania.

Research-based pharmaceutical companies representatives

Giancarlo Francese

Teva Pharmaceuticals

Giancarlo Francese has several years’ experience in R&D Pharmaceutical Industry drug development in early, late, launch, and post-marketing stages. His focus and expertise is on Global Health programs in partnership with external Global Health key players. Within Novartis, he worked in collaboration with external organizations for the development and introduction of new Tropical Medicines with a special focus on Malaria innovative treatments for adult and pediatric populations. With his team, he pioneered and implemented innovative R&D approaches for cost saving expanding drug accessibility to all. Giancarlo now is a member of the Teva Pharmaceuticals Ltd Social Impact and Responsibility group. He is based in Basel Switzerland. In his role, he leads the newly created Teva Access program: a key tenet of Teva as social impact strategy. In his role, he works on strategic partnerships with Global Health stakeholders to establish shared value initiatives. This work is intended to increase medicine access effectively to address unmet medical needs in LMICs. Giancarlo holds an MSc in Chemistry from Pavia University in Italy and a PhD in Supramolecular Chemistry from Bern University in Switzerland.

Generics companies representatives

Dominic De Souza

Sandoz

Dominic De Souza holds the position of Global Head, Anti-Infectives Sustainability and AMR Program, at Sandoz, the  Novartis generics division. In this role, Dominic leads the Sandoz and Novartis wide AMR Program, which focuses efforts across all four pillars of the global response: manufacturing, access, responsible use, and innovation. In addition, he is responsible for driving the sustainable development of the antibiotics portfolio at Sandoz, the largest provider of generic antibiotics globally. Dominic joined Sandoz 15 years ago and has held progressive roles across the product life-cycle, ranging from  development via production management to commercial. He is based in Kundl, Austria, the global production hub of the Sandoz Anti-Infectives business. Dominic holds a doctorate degree in Organic Chemistry from the University of Technology in Graz, Austria. Dominic´s high interest in and motivation for the field of AMR is linked to his personal vision that his kids will one day look back and judge that the global medical and pharmaceutical community paid adequate attention and jointly took the right actions to tackle AMR, which he considers to be the biggest silent threat to human health, along with climate change.

Generics companies representatives

Chuck Koon

Viatris

Charles Koon (“Chuck”), Head of Global Operations Auditing, Clinical Quality and Regulatory Intelligence for Viatris, has over 29 years of experience in the pharmaceutical industry. He has served in various capacities within site and global quality functions and played a fundamental role in transitioning Legacy Mylan from a U.S.-focused company to a global organization. Since Mylan’s transition to Viatris, Chuck has lead his team to achieve the goal of delivering increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance, along with striving towards empowering people worldwide to live healthier at every stage of life.

Beginning his career in 1992 as a Quality Control Chemist with Mylan Pharmaceuticals, he has held numerous managerial roles of increasing responsibility over the years throughout Quality Operations. As Mylan progressed into a global organization, Chuck was integral in the vision and development of Global Quality including operational, compliance, and systems development functions. This included development of the organizational structure, mapping of key systems and processes, and implementation and oversight of globally harmonized systems such as complaints management, internal and external cGMP auditing, change control, and investigations.

In 2016, Chuck was appointed as Head of Global Operations Auditing, Clinical Quality and Regulatory Intelligence for Viatris. Chuck had previously led these departments for Legacy Mylan since inception.  For Viatris, he will continue to manage an internationally-based team with specialties in GMP, GCP, GLP, GPvP, GDP, EHS, and Regulatory Affairs compliance with a focus on standardized, coordinated, and objective auditing services designed to evaluate Viatris’ operations related to compliance with regulations, internal policies, best practices, and industry standards.

In the area of Regulatory Intelligence, Chuck oversees the development and delivery of consistent and standardized adult learning on global policies, corporate training initiatives, industry trends identified via regulatory intelligence, and quality culture.

In addition to his current responsibilities, Chuck collaborates with the Global Social Responsibility team to ensure that the most accurate data is captured and reflected in the annual GSR submission. Also, he has participated in the FDA Generic Drug User Fee (GDUFA) development process, been a key member in supporting major due diligence projects, and continues to be involved in industry-leading efforts to establish one global high quality standard for all Viatris products, raise quality standards for all drug manufacturers globally, and expand the world’s access to affordable, quality medicines for patients worldwide

He holds both Bachelor of Science and Master of Science degrees from West Virginia University.

Generics companies representatives

Alba Tiley

Centrient Pharmaceuticals

Alba leads the Sustainable Antibiotics program at Centrient Pharmaceuticals where she works on sustainability and health issues such as antimicrobial resistance and environment, access to life-saving antibiotics and appropriate use. She represents Centrient Pharmaceuticals in industry platforms and within multi-stakeholder initiatives. Internally, she drives sustainability throughout the organization by coordinating local sustainability champions and sharing the impact of the global effort across the company. Alba has a Master’s degree in Strategic Management from the Rotterdam School of Management.

Generics companies representatives

Jean-Louis Tissier

bioMérieux

Jean-Louis is Vice President, Public and Government Affairs – AMR at bioMérieux since 1 October 2019. He joined the company 35 years ago holding roles of increasing responsibility, most recently as Vice President Global Marketing in Microbiology (2007-2011) and Vice President Northern Europe (2011-2019) which allowed him to accumulate rich experience in the field of in vitro diagnostics. Jean-Louis graduated from the Business School of the Conservatoire National Des Arts et Métiers in Paris and received his Master degree in Biology from the University of Paris.

Diagnostics companies representatives

Adam Zerda

Becton, Dickinson and Company (BD)

Adam Zerda is Director, Antimicrobial Resistance (AMR) Strategy and Development for BD. BD efforts to help combat AMR include a broad portfolio of solutions strategically positioned to play an active role in addressing this threat. In his role, Adam is responsible for developing and executing BD’s strategy for combatting the challenge of AMR globally by working to help build awareness of AMR, engage external stakeholders in policy and advocacy efforts around AMR, and develop training and process improvement programs, focusing specifically on infection prevention and antimicrobial stewardship. In leading BD’s AMR efforts, Adam is accountable for developing and implementing organization-wide, cross-functional alignment around this issue by working collaboratively with businesses, regions and functions. Prior to this role, Adam has held positions in business development, strategic innovation and research and development at BD. He joined the company in 2007. Prior to BD, Adam held roles in product development for GE Plastics. Adam has a Ph.D. in Polymer Science and Engineering (2002) from the University of Massachusetts in Amherst and a B.S. in Chemistry (1998) from TCU. He is based in North Carolina where he additionally sits on the board of North Carolina BIO.

Diagnostics companies representatives

Anand Anandkumar

Bugworks

Anand is co-founder and CEO of Bugworks, an Indo-USA pharma start-up, one of a handful of companies working on developing novel classes of antibiotics to tackle the global problem posed by multi-drug resistant bacterial superbugs. The company’s lead asset, entering clinical development during Q2 2021, is a novel dual target inhibitor with excellent potency against the entire list of WHO critical, high and medium threat pathogens. The company has won many national and international innovation awards including the Best start-up in India (2015), Economic Times Top Innovator award (2017), first company outside North America and Europe to win the coveted CARB-X grant, and has been featured in the CB-InSights 2019 list of top 36 global start-ups. Bugworks has prominently featured on leading global platforms including the BBC, Wellcome Trust, UNCTAD, CDC and Forbes.

Anand was previously co-founder and Managing Director, Cellworks, a company specializing in personalized oncotherapy, using mathematical modelling frameworks. He is also the Co-founder of the India semiconductor association (IESA), Vice-President & Member of Executive committee of India Biotech association (ABLE), member of Eta-Kappa-Nu and Tau-Beta-Pi International Engineering honours societies, member of the board of AMR Industry Alliance and member of the India advisory council of GARDP.

Biotechnology companies/SMEs representatives

Greg Frank

Biotechnology Innovation Organization (BIO)

Greg Frank is Senior Director of Infectious Disease Policy, where he is responsible for BIO’s antimicrobial resistance (AMR), vaccine regulatory, and vaccine reimbursement policy. His role includes leading a group of over 50 BIO member companies to develop policy solutions that address AMR. Dr. Frank serves on the Presidential Advisory Committee on Antibiotic Resistant Bacteria and expert advisory committees of the Access to Medicines Foundation AMR Benchmark, the Global AMR R&D Hub, the National Institute of Antimicrobial Resistance Research and Education, and the Partnership to Fight Infectious Diseases.  Prior to joining BIO, Dr. Frank served as Program Officer for Science and Research policy at the Infectious Diseases Society of America (IDSA), where Dr. Frank led policy initiatives on the infectious disease physician scientist workforce, dual use research of concern, and improving the development and clinical integration of infectious disease diagnostics that can address AMR. Dr. Frank received his doctorate in immunology at the University of Pittsburgh and pursued his postdoctoral training at the Laboratory of Viral Diseases at the National Institute of Allergy & Infectious Diseases.

Biotechnology companies/SMEs representatives